Skip to main content

Site notifications

(Approval lapsed) Emtricitabine/Tenofovir disoproxil Teva 200 mg/245 mg Film-coated Tablets (TEVA UK Ltd)

Section 19A approved medicine
(Approval lapsed) Emtricitabine/Tenofovir disoproxil Teva 200 mg/245 mg Film-coated Tablets (TEVA UK Ltd)
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 516
Phone
1800 181 060
Approved until
Status
Expired
Medicines in short supply/unavailable
TENOFOVIR DISOPROXIL EMTRICITABINE MYLAN 300/200 tenofovir disoproxil maleate300 mg and emtricitabine 200 mg film coated tablet bottle - ARTG 265834
Indication(s)
  • Treatment of HIV-1 infection: Emtricitabine/Tenofovir disoproxil is indicated for the treatment of HIV infected adults over the age of 18 years, in combination with other antiretroviral agents.
  • Pre-exposure prophylaxis (PrEP): Emtricitabine/Tenofovir disoproxil is indicated in combination with safer sex practices for preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and in heterosexual serodiscordant couples.
Published

Help us improve the Therapeutic Goods Administration site